Anti-nerve growth factor antibodies and methods of preparing and using the same
AssigneeNexvet Australia Pty Ltd
InventorDavid Gearing
Life of this patent
Estimating the term…
Abstract
A method of preparing an antibody suitable for use in an equine is provided. Also provided are equinised antibodies which specifically bind to equine neuronal growth factor (NGF) and neutralise the ability of equine NGF to bind to the p75 or TrkA equine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in an equine using said antibodies and/or nucleic acids.
Claims45
1-5. (canceled)
A neutralizing antibody or an antigen binding fragment thereof which is capable of specifically binding to equine nerve growth factor (NGF) wherein the antibody or antibody binding fragment comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1 or an amino acid sequence which has an identity of at least 85% thereto and/or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence which has an identity of at least 85% thereto.
An anti-equine NGF antibody, or equine NGF binding fragment thereof, the antibody or antibody binding fragment comprising a light chain variable region comprising at least one of:
- an FR1 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:10;
- an FR2 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:11;
- an FR3 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:12;
- and
- an FR4 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:13;
- and/or a heavy chain variable region comprising at least one of:
- an FR1 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:14;
- an FR2 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:15;
- an FR3 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:16;
- and
- an FR4 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:17;
(canceled)
An antibody or binding fragment thereof which specifically binds to one or more equine soluble proteins wherein the antibody does not mediate downstream effector functions and wherein the antibody is purifiable by binding to Protein A.
(canceled)
A method for treating, inhibiting or ameliorating pain in an equine, the method comprising the steps of:
- providing a therapeutically effective amount of an anti-equine NGF antibody, or antigen binding fragment thereof, wherein the antibody is an equinised antibody, and administering the same to an equine in need thereof.
44-45. (canceled)
48-69. (canceled)
-97. (canceled)
Dependencies are inferred from the claim text.